Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HKSE:08247'
s Net Margin % Range Over the Past 10 Years
Min: -27.8 Med: -0.51 Max: 8.53
Current: -27.8
HKSE:08247's Net Margin % is ranked worse than 68.81% of 202
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.705
vs HKSE:08247: -27.80
Biosino Bio-Technology and Science (HKSE:08247) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Biosino Bio-Technology and Science Net Margin % Related Terms
Biosino Bio-Technology and Science Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biosino Bio-Technology and Science Net Margin % Chart
HKSE:08247 vs TMO, DHR, IDXX: Net Margin % Comparison
For the Diagnostics & Research subindustry, Biosino Bio-Technology and Science's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biosino Bio-Technology and Science Net Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Biosino Bio-Technology and Science's Net Margin % distribution charts can be found below:
* The bar in red indicates where Biosino Bio-Technology and Science's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biosino Bio-Technology and Science (HKSE:08247) has a Net Margin % of -37.49% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Biosino Bio-Technology and Science and its competitors. According to the industry distribution chart, Biosino Bio-Technology and Science ranks #139 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 68.8%.
Is Biosino Bio-Technology and Science's Net Margin % too high?
Biosino Bio-Technology and Science's current Net Margin % is -37.49%. Based on the distribution chart, Biosino Bio-Technology and Science ranks #139 out of 202 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Biosino Bio-Technology and Science has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biosino Bio-Technology and Science's Net Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Biosino Bio-Technology and Science ranks #139 out of 202 companies for Net Margin %. This places Biosino Bio-Technology and Science in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Diagnostics & Research company?
A good Net Margin % depends on the Medical Diagnostics & Research industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Biosino Bio-Technology and Science and its competitors. Biosino Bio-Technology and Science's current Net Margin % is -37.49%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biosino Bio-Technology and Science stock overvalued right now?
Based on GuruFocus' analysis, Biosino Bio-Technology and Science (HKSE:08247) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.44, compared to a current price of HK$3.17 — trading 619.3% above its estimated fair value. The current Net Margin % is -37.49%. Biosino Bio-Technology and Science's overall GF Score™ is 37/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Biosino Bio-Technology and Science (HKSE:08247), the current Net Margin % is -37.49% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biosino Bio-Technology and Science (HKSE:08247) Overvalued in 2026?
Based on GuruFocus' analysis, Biosino Bio-Technology and Science stock appears to be overvalued.
The current stock price of HK$3.17 is trading 619.3% above its estimated GF Value™ of HK$0.44.
GuruFocus considers Biosino Bio-Technology and Science to be Significantly Overvalued.
Key valuation signals for HKSE:08247:
Net Margin %: -37.49%
GF Value™: HK$0.44 vs. price of HK$3.17 (619.3% above fair value)
No single metric tells the full story. See the HKSE:08247 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biosino Bio-Technology and Science Inc is engaged in the manufacture, sale, and distribution of IVD reagent products. The company operates in a single segment, the in-vitro diagnostic products segment, which manufactures, sells, and distributes a variety of mono/double diagnostic products. Geographically, it generates the majority of the revenue from Mainland China.
37GF Score
Get the complete analysis for HKSE:08247
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:08247 has been successfully added to your 
